文献速递骨质疏松与代谢性骨病骨肿瘤

抗骨吸收治疗预防绝经后早期乳腺癌患者芳香化酶抑制剂所致骨丢失

Prevention of aromatase inhibitor-induced bone loss with anti-resorptive therapy in post-menopausal women with early-stage breast cancer.
PubMed 文献 · Osteoporos Int · 2023-01-30

这项前瞻性纵向真实世界研究纳入168例绝经后雌激素受体阳性早期乳腺癌患者,评估抗骨吸收治疗对芳香化酶抑制剂所致骨丢失的预防作用。接受抗骨吸收治疗者24个月后股骨骨密度增加6.28%、腰椎骨密度增加7.79%;未接受治疗者股骨和腰椎骨密度均显著下降,多因素模型中未接受抗骨吸收治疗是股骨重大骨丢失的唯一预测因素(OR 20.83,95%CI 4.2-100,P<0.001)。

要点

  • 接受抗骨吸收治疗者24个月后股骨骨密度增加6.28%、腰椎骨密度增加7.79%。
  • 未接受抗骨吸收治疗者股骨和腰椎骨密度均显著下降,与基线骨密度无关。
  • 未接受抗骨吸收治疗是股骨重大骨丢失的唯一预测因素(OR 20.83)。

核心结论

  • 真实世界研究证实,接受芳香化酶抑制剂治疗的绝经后早期乳腺癌患者中,抗骨吸收治疗可显著增加股骨和腰椎骨密度,且与基线骨密度无关。
  • 未接受抗骨吸收治疗的患者发生重大骨丢失的风险增加约20.8倍。
  • 开始抗骨吸收治疗的最佳阈值尚未确定。

研究设计与样本

  • 前瞻性纵向研究,真实世界环境,随访2年。
  • 共328例患者转诊至研究中心,168例纳入研究,年龄67.7±10.6岁。
  • 144例符合抗骨吸收治疗条件。
  • 基线评估包括临床评估、生物学评估、骨密度测量和脊柱X线检查。
  • T值<-2或T值<-1.5 SD且伴有其他骨质疏松危险因素的患者接受抗骨吸收治疗处方。

主要发现

  • 接受抗骨吸收治疗的患者24个月后股骨骨密度增加6.28%,腰椎骨密度增加7.79%。
  • 骨密度增加在骨质疏松症和骨量减少症患者之间无显著差异。
  • 未接受抗骨吸收治疗的患者股骨和腰椎骨密度均显著下降,无论基线骨密度如何。
  • 多因素逻辑回归模型中,未接受抗骨吸收治疗是股骨重大骨丢失的唯一预测因素,OR为20.83(95%CI 4.2-100,P<0.001)。

关键数值与推荐

  • 抗骨吸收治疗处方标准为T值<-2或T值<-1.5 SD且伴有其他骨质疏松危险因素。
  • 未接受抗骨吸收治疗者重大股骨骨丢失的OR为20.83(95%CI 4.2-100,P<0.001)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 开始抗骨吸收治疗的最佳阈值尚未确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: We assessed if antiresorptive treatment can prevent aromatase inhibitor-induced bone loss in patients with early breast cancer. We observed that patients who did not receive antiresorptive treatment had a 20.8-fold increase in risk of bone loss after 24 months of aromatase inhibitors therapy. PURPOSE: This study aimed to describe changes in femoral and lumbar bone mineral density (BMD) after 24 months of aromatase inhibitors (AIs) and antiresorptive treatment in postmenopausal women with estrogen receptor-positive breast cancer. METHODS: Prospective, longitudinal study in a real-life setting with a 2-year follow-up. Patients underwent a complete baseline bone assessment including clinical assessment, biological evaluation, BMD measurement, and spine X-ray. Antiresorptive treatment was prescribed to patients with a T-score < - 2 or a T-score < - 1.5 SD with additional osteoporosis risk factors. A follow-up bone assessment was carried out after 24 months. RESULTS: Among 328 patients referred to our center, 168 patients (67.7 ± 10.6 years) were included in our study, and 144 were eligible for antiresorptive treatment. After 24 months, patients receiving antiresorptive treatment experienced a significant increase of + 6.28% in femoral-BMD (F-BMD) and + 7.79% in lumbar-BMD (L-BMD). This increase was not significantly different between osteoporotic and osteopenic patients. Conversely, patients not receiving antiresorptive treatment presented significant F-BMD and L-BMD loss regardless of the baseline BMD. In the multivariate logistic model, the lack of antiresorptive treatment was the only predictive factor for major femoral bone loss with a 20.83 odds ratio (CI95%:4.2-100, p < 0.001). CONCLUSION: This real-life study confirmed that antiresorptive treatment significantly increases femoral and lumbar BMD regardless of the baseline BMD in postmenopausal patients receiving AIs for early breast cancer. Patients who did not receive antiresorptive treatment had a 20.8-fold increased risk of major bone loss. Nevertheless, the best threshold to adopt for starting antiresorptive agents remains undetermined.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Mugnier B, Goncalves A, Daumas A, et al. Prevention of aromatase inhibitor-induced bone loss with anti-resorptive therapy in post-menopausal women with early-stage breast cancer. Osteoporos Int. 2023. PMID: 36715715. doi:10.1007/s00198-023-06683-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。